NMN or NR: Does It Matter Which You Take?

If you have decided to raise your NAD, the next question is which precursor to use: NMN or NR. Search results will hand you a confident winner within seconds. A more useful starting point is the one human study that gave both at the same dose and watched the marker everyone argues about. At 1 g a day for two weeks, NMN and NR did the same thing to it ⁴.

That marker is whole-blood NAD, and raising it is the entire pitch for both compounds. Neither has been shown to make a person live longer, or to shift energy, physical function or quality of life in a way a trial could measure. So the "which is better" debate sits upstream of any benefit anyone has demonstrated in people. Here is what each did in human trials, what genuinely separates them for a buyer, and where the evidence runs out.

Does it matter which one you take?

The most useful evidence is now a head-to-head. Christen and colleagues randomised 67 healthy adults, 65 of whom were analysed, to 1 g of NMN, 1 g of NR, 500 mg of nicotinamide or placebo daily for 14 days ⁴. Both NMN and NR raised whole-blood NAD to about twice baseline. On the single number both are marketed on, they finished at comparable levels, with no gap large enough to separate them.

The groups were small: 15 people on NMN, 16 on NR. Allocation was open-label, the run was two weeks, and the study measured circulating metabolites plus an ex vivo faecal fermentation model. It did not measure ageing, sustained energy or physical function. NAD-related compounds do fall in human tissue with age ¹, which is why raising them looks worth studying at all, though a two-week bump in a blood marker is a long way from that.

What does NMN actually show in people?

NMN is the more studied of the two in humans to date, and pooling those trials cools the story. A 2025 systematic review of eight randomised NMN trials found no significant pooled effect on fasting glucose, fasting insulin, glycated haemoglobin, insulin resistance or lipids ⁵. The trials were short and the populations varied.

The one frequently cited positive result is narrow. In a 2021 trial, 250 mg of NMN daily for ten weeks improved skeletal-muscle insulin sensitivity in postmenopausal women with overweight or obesity and prediabetes; 13 of 25 received NMN, and hepatic insulin sensitivity and body composition did not shift ⁶. That is a specific finding in a specific group, and it does not carry over to a healthy adult who simply wants more day-to-day energy. NMN can raise a pathway biomarker in short trials; whether that becomes something a person feels is still unproven.

What does NR actually show in people?

NR has its own placebo-controlled human data, and it tells a similar story. In a 2018 crossover trial, six weeks of NR raised NAD-related metabolites in the blood cells of 24 healthy middle-aged and older adults, with cardiovascular findings that were exploratory and needed confirmation ⁷. The controlled biomarker and tolerability evidence was the real contribution.

A 2019 study is the cleaner illustration. Twelve older men took 1 g of NR daily for 21 days, which changed the skeletal-muscle NAD metabolome and gene-expression signatures without changing mitochondrial function ⁸. That is target engagement without the downstream result the mechanism might predict. Read alongside the head-to-head, NR has genuine biomarker evidence and nothing showing it beats NMN on an outcome a person would notice.

Isn't NMN "one step closer" to NAD?

This is the argument that sells NMN over NR: in the salvage pathway, NR is converted to NMN first, so NMN is "one step closer" to NAD. The chemistry is right. It predicts nothing about how much of either you absorb, or what happens in a person.

The mechanistic case has been pushed further. A 2019 paper reported a dedicated NMN transporter ²; a published critique argued the data did not support that reading ³. Even taken at face value, no such transporter has been shown to give NMN a clinically meaningful edge in humans. In the head-to-head, the pathway argument predicts NMN should raise NAD more than NR; it did not ⁴.

What actually separates NMN and NR for a buyer?

With the biomarker a draw and the outcomes unproven for both, the decidable differences are practical. The clearest one in New Zealand is availability. Our range carries two NMN products and no NR: a higher-dose capsule, Super NMN 500 mg, and a lower-dose liposomal liquid, Quicksilver NAD+ Gold. The tenfold gap in labelled NMN between them is worth weighing on cost and routine, and it does not convert into a tenfold difference in absorption or effect.

Regulatory status also currently runs NMN's way, though it endorses nothing. New Zealand supplements carry no pre-market approval, so the sponsor is responsible for quality and safety ⁹. Australia added NMN to its permissible ingredients in December 2025 with conditions such as adults only, 500 mg a day and a 12-week cap ¹⁰. The US FDA concluded in September 2025 that NMN was not excluded from the supplement definition on the evidence before it ¹¹.

None of that is a verdict on safety or effectiveness, and none of it sets New Zealand law. What it does explain is why NMN, rather than NR, is the precursor you can readily buy here.

The bottom line

For an NAD precursor bought in New Zealand, the choice between NMN and NR is smaller than the marketing implies. At equal doses both raised blood NAD to about double in the one human trial that compared them, and neither has been shown to lengthen or improve a human life ⁴. That makes both a bet on plausible biology rather than a proven intervention.

So decide on what is knowable: the labelled amount, the format, the serving count, the purity documentation and the daily cost. Ranking the two from pathway diagrams or delivery claims is the part the evidence will not back up. If you want the shortlist, our Energy and Longevity collection stocks NMN in both a capsule and a liquid, with no NR to weigh up.

References

¹ Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE. 2012;7(7):e42357. DOI: 10.1371/journal.pone.0042357. PMID: 22848760.

² Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. 2019;1:47-57. DOI: 10.1038/s42255-018-0009-4. PMID: 31131364.

³ Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nature Metabolism. 2019;1:660-661. DOI: 10.1038/s42255-019-0085-0.

⁴ Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8:62-73. DOI: 10.1038/s42255-025-01421-8.

⁵ Chen F, Zhou D, Kong APS, et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials. Current Diabetes Reports. 2025;25:4. DOI: 10.1007/s11892-024-01557-z. PMID: 39531138.

⁶ Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. DOI: 10.1126/science.abe9985. PMID: 33888596.

⁷ Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. DOI: 10.1038/s41467-018-03421-7. PMID: 29599478.

⁸ Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717-1728.e6. DOI: 10.1016/j.celrep.2019.07.043. PMID: 31412242.

⁹ Medsafe. Regulation of dietary supplements. New Zealand Medicines and Medical Devices Safety Authority. Accessed 21 July 2026.

¹⁰ Therapeutic Goods Administration. NAD, NAD+, NADH or NMN medicines sold in Australia. Updated 3 February 2026.

¹¹ US Food and Drug Administration. Response to citizen petition FDA-2023-P-1867. 29 September 2025.

This article describes findings from published research for general educational purposes. It is not medical advice, and nothing here is intended to diagnose, treat, cure, or prevent any disease. If you take prescription medication or have a health condition, consult a qualified healthcare professional before adding a supplement.